Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?
Viatris (VTRS) and Eli Lilly (LLY) raised 2026 sales forecasts. Lilly increased its revenue forecast to $91.5B, while Viatris raised its forecast to $14.75B. Lilly's growth is driven by Mounjaro and Zepbound, while Viatris focuses on generics and potential blockbuster drugs. Lilly has higher margins and lower debt, but Viatris trades at a lower valuation.
How this was made
The 30-second read
Why it matters
Lilly's sizable revenue uplift reinforces its growth narrative, likely supporting price gains, while Viatris' small lift amid operational challenges may limit upside.
Market read
Guidance updates for two major pharma stocks provide actionable insight for sector rotation strategies.
What to watch
Potential upside from upcoming Phase III trials (selatogrel, cenerimod) and the Pacira acquisition could improve Viatris' pipeline.
Background
The article compares the 2026 guidance lifts of Viatris and Eli Lilly, noting differences in growth, margins, debt, and pipeline prospects.
Ticker impact
Viatris raised its 2026 revenue forecast to $14.75 bn, a modest lift amid thin margins and supply‑chain disruptions.
limited upside as investors weigh higher debt and supply risks
The forecast increase is small (≈0.3% revenue lift) and comes with a $100‑150 m supply hit, suggesting modest market reaction.
Eli Lilly moved its 2026 revenue midpoint to $91.5 bn, up from $86 bn, and trimmed EPS guidance due to one‑time items.
upward pressure as higher revenue outlook outweighs EPS trim
A $5.5 bn revenue increase (≈6% lift) is material for a high‑growth pharma, and one‑time items are excluded, so investors may price in growth.
Market effects
Both updates highlight divergent trajectories in the pharma sector: high‑growth innovators vs. generic/legacy players.
U.S. pharma stocks may see relative rotation between growth and value names.
Limited to investors tracking major U.S. drugmakers; no broader macro effect.
Counterpoint
Viatris' modest raise could be a buying opportunity if the market over‑reacts to its supply‑chain issues.
Key entities
- companyViatris
Generic drugmaker raising modest 2026 guidance.
- companyEli Lilly
Innovative pharma with large revenue uplift for 2026.
